Dr. Lal Pathlabs Share Price
1878.50-46.70 (-2.43%)
+12.57% past 1 Year
News
Dr Lal Pathlabs forms overseas subsidiary in Tashkent, Uzbekistan market entry
Equity
LALPATHLAB
Dr Lal Pathlabs signals stronger mid-teen growth outlook and margin upside
Equity
LALPATHLAB
Dr Lal Pathlabs plans aggressive capex for new labs and radiology expansion
Equity
LALPATHLAB
Dr Lal PathLabs sees mid teens FY revenue growth after strong Q1
Equity
LALPATHLAB
Dr Lal Pathlabs announces Rs 5 per share dividend approval
Equity
LALPATHLAB
Dr Lal Pathlabs posts strong Q1 FY earnings with robust revenue growth
Equity
LALPATHLAB
Dr Lal Pathlabs reports higher quarterly EBITDA and improved margin
Equity
LALPATHLAB
Dr Lal Pathlabs posts strong Q1 FY earnings with robust profit growth
Equity
LALPATHLAB
Dr Lal PathLabs sees Rs 25.89 crore NSE block trade in equity shares
Equity
LALPATHLAB
Dr Lal PathLabs board to consider Q1 FY27 results on July 24
Equity
LALPATHLAB
Dr. Lal Pathlabs incorporates wholly owned subsidiary in Dubai
Equity
LALPATHLAB
Block deal in Dr. Lal Path Labs shares on NSE worth Rs 20.56 crores
Equity
LALPATHLAB
Dr. Lal PathLabs Guides for FY27 EBITDA Margin at 27-28%.
Equity
LALPATHLAB
Dr. Lalpath Labs Guides 13-15% Revenue Growth for FY27, No Price Hikes Planned
Equity
LALPATHLAB
Goldman Sachs Recommends Sell on Dr. Lal Pathlabs with Rs 1,300 Target Amid Q4 Margin Pressure
Equity
LALPATHLAB
Nomura recommends Buy on Dr. Lal Pathlabs with Rs 1,860 target on Q4 revenue beat.
Equity
LALPATHLAB
Dr. Lal PathLabs informs about update on acquisition
Equity
LALPATHLAB
Dr. Lal Pathlabs - Quaterly Results
Equity
LALPATHLAB
Dr Lal Pathlabs Reports Q4 Revenue of Rs 700 Crores, Up from Rs 603 Crores YoY.
Equity
LALPATHLAB
Dr Lal Pathlabs Q4 Consolidated Net Profit Declines to Rs 130 Crores YoY
Equity
LALPATHLAB